Patients with end-stage kidney disease on maintenance hemodialysis frequently require iron supplementation to compensate for ongoing iron losses, and to maintain hemoglobin levels with or without additional use of erythropoiesis-stimulating agents (ESA). The investigators aim to compare two different intravenous iron preparations, ferric carboxymaltose and iron sucrose in 140 hemodialysis patients. The investigators primary objective is to assess whether both agents are equally effective to maintain a target haemoglobin within 10-12 mg/dl. The investigators will also measure ferritin, transferrin, transferrin saturation, and how much ESA therapy is administered. Patients will be randomly assigned to either treatment group and followed in parallel over an active study period of 40 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
143
Medical University of Vienna, Division of Nephrology and Dialysis
Vienna, Austria
Wiener Dialysezentrum GmbH
Vienna, Austria
Serum hemoglobin level (g/dl)
Time frame: 40 weeks
Serum ferritin level (µg/l)
Time frame: Week 0, 10, 20, 30, 40
Serum transferrin level (mg/dl)
Time frame: Week 0, 10, 20, 30, 40
Serum level of transferrin saturation (TSAT) (%)
Time frame: Week 0, 10, 20, 30, 40
ESA consumption in I.E./week or µg/week as appropriate
Time frame: Week 0, 10, 20, 30, 40
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.